PF-08634404

Multispecific antibody

Also known as SSGJ-707

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-02-27.

Also in development:Colorectal Cancer · Phase 3Endometrial Cancer · Phase 3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Colorectal Cancer
Endometrial Cancer
Non-Small Cell Lung Cancer
NCT06980272 · Shenyang Sunshine Pharmaceutical Co., LTD.
2025-06-20 – 2026-03-01 · Advanced Non-Small Cell Lung Cancer
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT07392892 · Pfizer
2026-05-14 – 2032-07-21 · Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
What this study did
Phase 2 (6)
Colorectal Cancer
NCT06493760 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2024-09-03 – 2027-06 · Metastatic Colorectal Cancer
What this study did
Endometrial Cancer
NCT06522828 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2024-10-10 – 2026-08 · Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07489066 · Pfizer
2026-06-30 – 2031-07-30 · Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
What this study did
NCT06412471 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2024-07-26 – 2025-08 · First-line Advanced NSCLC Patients
What this study did
NCT06361927 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2024-05-15 – 2025-07 · NSCLC
What this study did
Other / comorbidity
NCT07476287 · Pfizer
2026-07-02 – 2031-03-24 · Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Small Cell Lung, Small Cell Cancer Of The Lung
What this study did
Phase 1/2 (4)
Non-Small Cell Lung Cancer
NCT07227298 · Pfizer
2026-01-30 – 2033-08-23 · Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07227415 · Pfizer
2026-02-10 – 2028-11-01 · Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell Metastasis, Advanced or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Advanced, Metastatic Renal Cell Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic/Advanced Renal Cell Carcinoma
What this study did
NCT07227012 · Pfizer
2025-12-01 – 2028-10-17 · Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms, Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
What this study did
NCT07421700 · Pfizer
2026-03-11 – 2028-09-25 · Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Colorectal Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
PF-08634404: this drugPhase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
NCT02314819: Median overall survival 9.3 months with fruquintinib (95% CI 8.2 to 10.5) vs 6.6 months with placebo (95% CI 5.9 to 8.1); HR 0.65 (95% CI 0.51 to 0.83), P<.001 (published analysis)
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Weak signal
NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
BecotatugPhase 3Monoclonal antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
IBI363Phase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
INCA33890Phase 3Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 3Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 2/3PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
IBI305Phase 2Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
SirexatamabPhase 2Monoclonal antibodyDKK1 (Dickkopf-1)not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
CR-001
Phase 1/2(overall)
Multispecific antibodyPD-1 + VEGF
not yet graded(overall)
No reviewed efficacy summary in this indication
NC410
Phase 1/2(overall)
Protein / enzyme therapeuticCollagen (LAIR-1 ligands)not yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T Cell
Phase 1(overall)
Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY01008Phase 1Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
PI3Kalpha Precision Therapy
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow PF-08634404 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
October 2027 (1)
Phase 1/2Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms …Recruiting
Est. primary completion 2027-10-18 · NCT07227012 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1/2Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma …Recruiting
Est. primary completion 2027-11-02 · NCT07227415 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1/2Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial CarcinomaRecruiting
Est. primary completion 2027-12-28 · NCT07421700 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
Phase 2Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Small Cell Lung …Recruiting
Est. primary completion 2028-03-24 · NCT07476287 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-07-29 · NCT07489066 · CT.gov ↗
What to watch
2029 (3)
February 2029 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-27 · NCT07222566 · CT.gov ↗
What to watch
March 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-03-08 · NCT07227298 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Endometrial CancerRecruiting
Est. primary completion 2029-06-01 · NCT07578649 · CT.gov ↗
What to watch
2030 (2)
February 2030 (1)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2030-02-23 · NCT07222800 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2/3Small Cell Lung Cancer (SCLC)Recruiting
Est. primary completion 2030-06-14 · NCT07226999 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Phase 2/3Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer …Recruiting
Est. primary completion 2031-07-22 · NCT07392892 · CT.gov ↗
What to watch

See the full readout calendar ↗